CeNeS starts New Year

Many thanks for sharing that EJ.

It is posts like that which are very useful on bb's.

It is all very well hoping that m6g will be the new beez knees, and bring in billions for CENES overtime, but the reality is that morphine has stood the test of time over many years, and has helped many thousands of people from suffering.

m6g, if successful, will have a major role to play in post op care, but will likely be used alongside morphine in hospitals as a choice, as opposed to being an exclusive alternative.

This is still a very attractive proposition for the company and its shareholders, and if p3 trials are successful, we will own shares at a very low price to what they will be.

As a rule though, barely one in 50 of these small biotech companies make it big, if that, so it comes with high risk. The fact that CENES is more than a one trick pony helps, but my experience of these smaller biotech/pharm/healthcare companies has not been good so far.

I have what I hold and will let it ride until news of the p3 trials comes through in middish 2006, but whilst my hope levels are high, I will be pleasantly surprised if CENES does what we all want, and only hold a modest holding that won't bother me if it fails, but could be significant if it succeeds.

Good luck to all holders in 2006.

We either own one of the best potential performers on the LSE for next year, or a blue sky dream that has a poor ending. On that basis, CENES at current levels will either prove to be the biggest bargain on AIM right now, or one of many hundreds of smaller companies with a potential collossus, and a realistic white elephant.

I see it very much as an all or nothing holding, and on that basis am happy to hold. It is unlikely to be an active share in the early part of 2006 imo, unless tipped by one or more respectable media outlets.

all the best

FS